Cover Image
市場調查報告書

補體C5:開發中產品分析

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363122
出版日期 內容資訊 英文 107 Pages
訂單完成後即時交付
價格
Back to Top
補體C5:開發中產品分析 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 107 Pages
簡介

本報告提供補體C5藥物的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

補體C5概要

治療藥的開發

補體C5:開發中的產品 - 各開發階段

補體C5:開發中的產品 - 治療範圍別

補體C5:開發中的產品 - 各適應症

補體C5:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

補體C5:企業開發中的產品

補體C5:大學/機關開發中的產品

補體C5:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

補體C5治療藥的開發企業

  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Epirus Biopharmaceuticals, Inc.
  • InflaRx GmbH
  • Novartis AG
  • Noxxon Pharma AG
  • Ophthotech Corp.
  • Ra Pharmaceuticals, Inc.
  • Swedish Orphan Biovitrum AB

補體C5:藥物簡介

補體C5:暫停中的計劃

補體C5:中止開發的產品

補體C5:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1051TDB

Summary:

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5, 1 and 16 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Immunology, Hematological Disorders, Gastrointestinal, Ophthalmology, Cardiovascular, Infectious Disease, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Respiratory, Genetic Disorders and Other Diseases which include indications Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), Chronic Inflammation, Myasthenia Gravis, Sepsis, Age Related Macular Degeneration, Choroidal Neovascularization, Dry (Atrophic) Macular Degeneration, Inflammation, Intermediate Uveitis, Lupus Nephritis, Posterior Uveitis, Septic Shock, Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Autoimmune Disorders, Bacterial Pneumonia, Bacterial Sepsis, Benign Mucous Membrane Pemphigoid (Oral Cicatricial Pemphigoid), Bullous Pemphigoid, Cardiovascular Inflammation, Community Acquired Pneumonia, Duchenne Muscular Dystrophy, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Guillain-Barre Syndrome, Hidradenitis Suppurativa, Ischemia, Ischemia Reperfusion Injury, Juvenile Macular Degeneration (Stargardt Disease), Kidney Transplant Rejection, Lung Injury, Multiple Organ Failure, Neuromyelitis Optica (Devic's Syndrome), Peritonitis, Polypoidal Choroidal Vasculopathy, Pulmonary Edema, Sicca Syndrome (Sjogren), Thrombotic Microangiopathy, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome), Uveitis and Wet (Neovascular / Exudative) Macular Degeneration.

The latest report Complement C5 - Pipeline Review, H2 2017, outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
  • The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview
    • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development
    • Akari Therapeutics Plc
    • Alexion Pharmaceuticals Inc
    • Alnylam Pharmaceuticals Inc
    • Amgen Inc
    • F. Hoffmann-La Roche Ltd
    • InflaRx GmbH
    • ISU ABXIS Co Ltd
    • Novartis AG
    • NovelMed Therapeutics Inc
    • Noxxon Pharma AG
    • Ophthotech Corp
    • Ra Pharmaceuticals Inc
    • Regeneron Pharmaceuticals Inc
    • Swedish Orphan Biovitrum AB
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles
    • AcPepA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avacincaptad pegol sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bikaciomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cemdisiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Coversin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Coversin LA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IFX-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IFX-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Complement C5 for Age Related Macular Degeneration - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mubodina - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NM-9405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-19 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Inhibit Complement C5 for Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-101295 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-101348 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RA-101495 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ravulizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REGN-3918 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-6107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOBI-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Coversin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tesidolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Products
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products
  • Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 26, 2017: Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)
      • Sep 21, 2017: Akari Therapeutics Announces Regulatory Progress Following FDA Meeting
      • Sep 19, 2017: Ophthotech Provides Update on Zimura Complement Programs for Treatment of Eye Diseases
      • Sep 13, 2017: Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris (Eculizumab) Treatment for Patients with Refractory Generalized Myasthenia Gravis
      • Sep 07, 2017: InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa
      • Aug 21, 2017: European Commission Grants New Indication for Soliris (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG)
      • Aug 15, 2017: Alexion Receives Three New U.S. Patents for Soliris (eculizumab), Extending Patent Protection Into 2027
      • Jul 31, 2017: Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
      • Jul 26, 2017: Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases, Provides Update on Zimura
      • Jul 19, 2017: Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis
      • Jun 27, 2017: Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH
      • Jun 24, 2017: Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association
      • Jun 23, 2017: Alexion Receives Positive CHMP Opinion for Soliris for the Treatment of Patients with Refractory Generalized Myasthenia Gravis in the European Union
      • Jun 21, 2017: Ra Pharmaceuticals to Host Conference Call on Initial Phase 2 Data for RA101495 in PNH
      • May 18, 2017: Ra Pharmaceuticals to Present at the 22nd Congress of the European Hematology Association
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Akari Therapeutics Plc, H2 2017
  • Pipeline by Alexion Pharmaceuticals Inc, H2 2017
  • Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
  • Pipeline by Amgen Inc, H2 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Pipeline by InflaRx GmbH, H2 2017
  • Pipeline by ISU ABXIS Co Ltd, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by NovelMed Therapeutics Inc, H2 2017
  • Pipeline by Noxxon Pharma AG, H2 2017
  • Pipeline by Ophthotech Corp, H2 2017
  • Pipeline by Ra Pharmaceuticals Inc, H2 2017
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Pipeline by Swedish Orphan Biovitrum AB, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top